EXPANDING PUBLIC RESPONSIBILITIES OF SECURITIES LAWYERS - ANALYSIS OF NEW TREND IN STANDARD OF CARE AND PRIORITIES OF DUTIES

被引：10
|
作者：
LOWENFELS, LD [1 ]
机构：
[1] NEW YORK BAR ASSOC, NEW YORK, NY 10000 USA
来源：
COLUMBIA LAW REVIEW | 1974年 / 74卷 / 03期
关键词：
D O I：
10.2307/1121762
中图分类号：
D9 [法律]; DF [法律];
学科分类号：
0301 ;
摘要：
引用
收藏
页码：412 / 438
页数：27
相关论文
共 49 条
  • [41] The New Public Long-Term Care Insurance System in Japan - An analysis of policy-related issues one year after implementation
    Koyama, H
    Tsutsui, T
    Higashino, S
    Tatara, T
    GERONTOLOGIST, 2001, 41 : 302 - 303
  • [42] What proportion of patients need to be tested to realise test and treat goals? Trend analysis of patients screened for HIV within the New York City municipal health-care system
    Casey, E.
    Hamilton, T.
    Schechter, C.
    LANCET, 2013, 382 : 2 - 2
  • [43] COST-EFFECTIVENESS ANALYSIS OF THE NEW PCV-13 VACCINE WHEN COMPARED TO NO VACCINATION FROM A PUBLIC HEALTH-CARE SYSTEM PERSPECTIVE IN HONG KONG
    Lee, K. K.
    Chow, D. P.
    VALUE IN HEALTH, 2010, 13 (07) : A549 - A549
  • [44] The "One-to-Many" Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma
    Messori, Andrea
    Rivano, Melania
    Cancanelli, Luca
    Damuzzo, Vera
    Ossato, Andrea
    Chiumente, Marco
    Mengato, Daniele
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [45] PEMBROLIZUMAB VS. STANDARD OF CARE CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER WITH HIGH PD-L1 EXPRESSION LEVELS: A COST-UTILITY ANALYSIS FROM THE ONTARIO, CANADA PUBLIC PAYER PERSPECTIVE
    Chu, R.
    Tudor, R.
    Choi, D. S.
    Wong, O.
    Chan, K. K. W.
    Leighl, N. B.
    Chan, B. C. F.
    Coyte, P. C.
    Rebecca, H. H.
    VALUE IN HEALTH, 2023, 26 (06) : S259 - S259
  • [46] Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) is the New Standard of Care in the Treatment of Patients with Early Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) Trial HD10
    Mueller, R. P.
    Eich, H. T.
    Pluetschow, A.
    Debus, J.
    Bamberg, M.
    Wilbom, K.
    Eble, M.
    Mueller-Hennelink, H.
    Diehl, V.
    Engert, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S26 - S27
  • [47] Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10.
    Engert, Andreas
    Diehl, Volker
    Pluetschow, Annette
    Eich, Hans T.
    Herrmann, Richard
    Doerken, Bernd
    Kanz, Lothar
    Greil, Richard
    Markova, Jana
    Fuchs, Michael
    Borchmann, Peter
    Mueller-Hermelink, Hans Konrad
    Mueller, Rolf Peter
    BLOOD, 2009, 114 (22) : 299 - 299
  • [48] Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) HD10 study
    Engert, A.
    Diehl, V
    Pluetschow, A.
    Eich, H.
    Herrmann, R.
    Doerken, B.
    Kanz, L.
    Greil, R.
    Markova, J.
    Fuchs, M.
    Borchmann, P.
    Mueller-Hermeling, H. K.
    Mueller, R. P.
    ONKOLOGIE, 2010, 33 : 124 - 124
  • [49] TWO CYCLES OF ABVD FOLLOWED BY INVOLVED FIELD RADIOTHERAPY WITH 20 GRAY (GY) IS THE NEW STANDARD OF CARE IN THE TREATMENT OF PATIENTS WITH EARLY-STAGE HODGKIN LYMPHOMA: FINAL ANALYSIS OF THE RANDOMIZED GERMAN HODGKIN STUDY GROUP (GHSG) HD10 STUDY
    Engert, A.
    Pluetschow, A.
    Eich, H.
    Herrmann, R.
    Doerken, B.
    Kanz, L.
    Greil, R.
    Markova, J.
    Fuchs, M.
    Borchmann, P.
    Mueller-Hermelink, H.
    Mueller, R.
    Diehl, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 473 - 473
12345